Here are five thoughts:
1. The tax is expected to generate $29 billion over the next decade. The tax is comprised of a 2.3 percent levy on taxable medical devices’ sales price.
2. While the manufacturer pays the tax, the manufacturer will likely place the additional expenses onto purchasers, namely physicians and hospitals.
3. Nearly 166 Democrats voted alongside Republicans to approve the two-year delay. Ninety-five Republicans voted against the delay.
4. A large portion of senators who hailed from states with a high concentration of device manufacturers voted in favor of the delay.
5. Sen. Bernie Sanders (D-Vt.) and Sen. John McCain (R-Ariz.) were among those opposing the delay.
More articles on devices:
Medovex reports DenerveX System living tissue population test results: 6 key points
US spine implants market to grow at CAGR of 5.29% through 2020: 4 observations
Surgeon-driven innovation in spine surgery: TranS1 CEO on 2 new innovations & what the future holds
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
